All-cause mortality and progression risks to hepatic decompensation and hepatocellular carcinoma in patients infected with Hepatitis C virus

Clinical Infectious Diseases

Volumn 62, Issue 3, 2016, Pages 289-297

  Xu, Fujie ^a   Moorman, Anne C ^a   Tong, Xin ^a   Gordon, Stuart C ^b   Rupp, Loralee B ^b   Lu, Mei ^b   Teshale, Eyasu H ^a   Spradling, Philip R ^a   Boscarino, Joseph A ^c   Trinacty, Connie M ^d   Schmidt, Mark A ^d   Holmberg, Scott D ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c GEISINGER HEALTH SYSTEM   (United States)

^d KAISER PERMANENTE   (United States)

Author keywords

cirrhosis; hepatic decompensation; hepatitis C; hepatocellular carcinoma; mortality

Indexed keywords

ANTIVIRUS AGENT;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; ASCITES; CANCER DIAGNOSIS; CANCER MORTALITY; CHRONIC HEPATITIS C; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; ESOPHAGUS VARICES; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FIBROSIS; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; PORTAL HYPERTENSION; PRIORITY JOURNAL; UNITED STATES; BIOPSY; CARCINOMA, HEPATOCELLULAR; COMPLICATION; LIVER CIRRHOSIS; MIDDLE AGED; MORTALITY; PATHOLOGY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; YOUNG ADULT;

ADULT; AGED; BIOPSY; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE; MALE; MIDDLE AGED; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; UNITED STATES; YOUNG ADULT;

EID: 84962219691     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ860     Document Type: Article

References (25)

1. Jafri SM, Gordon SC. Care of the cirrhotic patient. Infect Dis Clin North Amer 2012; 26: 979-94
2. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-21
3. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-8
4. LyKN, Xing J, KlevensRM, JilesRB, Holmberg SD.Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. Clin Infect Dis 2014; 58: 40-9
5. American Association for the Study of Liver Diseases/Infectious Diseases Society of America /International AIDS Society-USA. When and in whom to initiate HCV therapy, 2014. Available at: http://www.hcvguidelines.org/node/91. Accessed 5 April 2015
6. Fried MW, Shiffman ML, Reddy KR., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82
7. Manos MM, Shvachko VA, Murphy RC, Arduino JM, Shire NJ. Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. J Med Virol 2012; 84: 1744-50
8. Van Der Meer AJ, Veldt BJ, Feld JJ., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93
9. Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 923-30
10. Chao D, Botwin G, Morgan TR. Update on recently approved treatments for hepatitis C. Curr Treat Options Gastroenterol 2014; 12: 211-28
11. Patient-Centered Outcomes Research Institute. Funding announcement: clinical management of hepatitis C infection. Available at: http://www.pcori.org/sites/default/files/PCORI-PFA-Hepatitis-C.pdf. Accessed 4 February 2015
12. Brennan T, Shrank W. New expensive treatments for hepatitis C infection. JAMA 2014; 312: 593-4
13. Simon T, Chung R. The new hepatitis C virus bottleneck: can delaying therapy be justified? Hepatology 2015; 62: 666-7
14. Moorman AC, Gordon SC, Rupp LB., et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the Chronic Hepatitis Cohort Study (CHeCS). Clin Infect Dis 2013; 56: 40-50
15. Holmberg SD, Lu M, Rupp LB., et al. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clin Infect Dis 2014; 57: 240-6
16. Gordon SC, Pockros PJ, Terrault NA., et al. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 2012; 56: 1651-60
17. Gordon SC, Lamerato LE, Rupp LB., et al. Antiviral therapy for chronic hepatitis B virus infection anddevelopment ofhepatocellular carcinomain aU.S.population, theChronic Hepatitis Cohort Study (CHeCS). Clin Gastroenterol Hepatol 2014; 12: 885-93
18. Mahajan R, Xing J, Liu SJ., et al. Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. Clin Infect Dis 2014; 58: 1055-61
19. Quan H, Sundararajan V, Halfon P., et al. Coding algorithms for defining comorbidities in ICD-9-10-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-9
20. Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Costeffectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 2015; 61: 1860-9
21. Sandrin L, Fourquet B, Hasquenoph JM., et al. Transient elastography: a newnoninvasivemethodforassessment ofhepatic fibrosis.UltrasoundMed Biol2003; 29: 1705-13
22. Bruno S, Zuin M, Crosignani A., et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-Term prospective study. Am J Gastroenterol 2009; 104: 1147-58
23. Di Bisceglie AM, Shiffman ML, Everson GT., et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429-41
24. Dienstag JL, Ghany MG, Morgan TR., et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011; 54: 396-405
25. Xu F, Tong X, Leidner AJ. Hospitalizations and costs associated with hepatitis C and advanced liver disease continue to increase. Health Aff 2014; 33: 1728-35